Doctors at Intermountain Health said Monday they were introducing a “cutting-edge” therapy they hoped would make a difference for patients with advanced melanoma skin cancer. Tumor-infiltrating lymphocyte (TIL) therapy is used to treat melanoma where the cancer cannot be surgically removed, or where it has spread. Dr. Caroline Nebhan, Intermountain Health medical oncologist, said the therapy featuring the new medicine AMTAGVI is a potential difference-maker for those with unresponsive melanoma.